Japan remains the world’s second-largest individual pharmaceutical market, characterized by a sophisticated regulatory environment and a rapidly aging population. For global pharmaceutical companies, entering this market is a high-reward venture that carries a significant responsibility: maintaining rigorous post-marketing safety standards. As we move into 2026, the Japanese regulatory landscape is evolving. With the PMDA (Pharmaceuticals and Medical…

The global pharmaceutical landscape is moving at a breakneck pace. For regulatory affairs (RA) teams, managing compliance is no longer just about tracking local updates; it is about keeping up with a constant stream of new guidelines, fee structures, and clinical submission frameworks across dozens of jurisdictions simultaneously. Historically, tracking these changes meant hours of…